News

Lundbeckfonden Ventures News

Cambridge, UK and Indianapolis, US – 15 October 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”) provides an update following receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in respect of its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) on 5 October 2018. “Our discussions...
FDA issued a Complete Response letter to Acacia Pharma on Friday 5 October Only issue raised relates to FDA inspection of contract manufacturer of active ingredient No other quality or manufacturing deficiencies noted No clinical safety or efficacy issues identified and no requirement for further clinical studies or data analyses Conference call scheduled for 09.30...
Lund, Sweden, 08:00 CET, 08 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces that its US commercial team will be showcasing CERAMENT®|BONE VOID FILLER (CERAMENT®|BVF) at two important US orthopedic conferences taking place in October. These marketing activities are taking place just ahead of the launch...
Pruritus Relief thru Itch-Scratch Modulation (PRISM) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic and other serious neurological conditions, today announced initiation of a pivotal clinical trial evaluating Nalbuphine ER in patients...
Lund, Sweden, 18:00 CET 28 September 2018 – During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 September 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,555,917. For more information contact: BONESUPPORT AB Emil...
Lund, Sweden, 08:00 CET, 19 September 2018 – Strategic review has led to important initiatives to strengthen BONESUPPORT’s US and European commercial platforms Excellent progress in creating own distributor network in the US. 18 new distributors contracted. 425 highly motivated sales reps to sell BONESUPPORT’s products from 21 October 2018   European commercial expansion on track...
Cambridge, UK and Indianapolis, US – 14 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial with BARHEMSYS(TM) (intravenous amisulpride) have been published in the online edition of the leading peer-reviewed journal Anesthesia & Analgesia (Candiotti et al1). Positive headline...
Cambridge, UK and Indianapolis, US – 7 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH) announces that it will hold a General Meeting of shareholders on 25 September 2018 at 10.00 a.m. BST at the offices of Stephenson Harwood LLP, 1 Finsbury Circus London EC4M 7SH,  in order to...
Cambridge, UK and Indianapolis, US – 7 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH) announces unaudited operating results for the half year ended 30 June 2018. Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and...
1 2 3 46

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)
15. October 2018
Acacia Pharma Group PLC – ACACIA PHARMA PROVIDES UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)
15. October 2018
BONESUPPORT to Showcase CERAMENT® BONE VOID FILLER at Two Upcoming US Orthopedic Conferences
15. October 2018